Hurtenbach U, Lier E, Adorini L, Nagy Z A
Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.
J Exp Med. 1993 May 1;177(5):1499-504. doi: 10.1084/jem.177.5.1499.
The role of antigen presentation as a possible mechanism underlying major histocompatibility complex (MHC) association of autoimmune disease has been studied in non-obese diabetic (NOD) mice. By screening for inhibition of antigen presentation to NOD T cell hybridoma, we have selected a synthetic peptide, yTYTVHAAHAYTYt (small letters denote D amino acids), that efficiently blocks antigen presentation by the NOD class II MHC molecule A alpha g7A beta g7 (Ag7) in vitro. The inhibition is MHC selective, in that it does not affect antigen presentation by the E(d) and E(k) molecules, and has only a marginal effect on presentation by the A(d) molecule. This peptide also inhibits the priming for Ag7-restricted T cell responses in vivo, and prevents the spontaneous development of diabetes in female NOD mice, when administered chronically from 3 wk of age on. Chronic treatment with a control peptide, KMKMVHAAHAKMKM, that fails to bind to Ag7 has no effect on the disease. These data indicate that antigen presentation by the Ag7 molecule plays a pivotal role in the induction of autoimmune diabetes. Furthermore, the results demonstrate that interference with antigen presentation by a class II molecule can prevent the onset of spontaneous autoimmune disease associated with the same molecule.
作为自身免疫性疾病主要组织相容性复合体(MHC)关联潜在机制的抗原呈递作用,已在非肥胖糖尿病(NOD)小鼠中展开研究。通过筛选对NOD T细胞杂交瘤抗原呈递的抑制作用,我们筛选出一种合成肽yTYTVHAAHAYTYt(小写字母表示D型氨基酸),该肽在体外能有效阻断NOD II类MHC分子Aαg7Aβg7(Ag7)的抗原呈递。这种抑制作用具有MHC选择性,即它不影响E(d)和E(k)分子的抗原呈递,对A(d)分子的呈递仅有轻微影响。该肽在体内也能抑制Ag7限制性T细胞应答的启动,并且从3周龄开始长期给药时,可预防雌性NOD小鼠糖尿病的自发发展。用不能与Ag7结合的对照肽KMKMVHAAHAKMKM进行长期治疗,对疾病没有影响。这些数据表明,Ag7分子的抗原呈递在自身免疫性糖尿病的诱导中起关键作用。此外,结果表明干扰II类分子的抗原呈递可预防与同一分子相关的自发自身免疫性疾病的发生。